Spondyloarthropathies: Targeting IL-17 in refractory PsA
- PMID: 28592895
- DOI: 10.1038/nrrheum.2017.94
Spondyloarthropathies: Targeting IL-17 in refractory PsA
Comment on
-
Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial.Lancet. 2017 Jun 10;389(10086):2317-2327. doi: 10.1016/S0140-6736(17)31429-0. Epub 2017 May 24. Lancet. 2017. PMID: 28551073 Clinical Trial.
References
-
- Lancet. 2017 Jun 10;389(10086):2317-2327 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous
